Research programme: hepatitis C therapy - Biota/GlaxoSmithKlineAlternative Names: Hepatitis C therapy research programme - Biota/GlaxoSmithKline
Latest Information Update: 23 Mar 2007
At a glance
- Originator Biota Inc
- Developer GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 12 Aug 2004 Discontinued - Preclinical for Hepatitis C treatment in USA (unspecified route)
- 12 Aug 2002 Preclinical trials in Hepatitis C treatment in USA (unspecified route)